EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Radiopharmaceutical Therapy–Linked Tumor Resistance: Immune Evasion, Nonimmune Mechanisms, and Immunometabolic Vulnerabilities

Evan R Abt, Caius G Radu, Johannes Czernin, Christine E Mona

Journal of Nuclear Medicine · 2026

DOI: 10.2967/jnumed.125.269489 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Nuclear Medicine, 2026. Verfasst von Evan R Abt und 3 weiteren Autor:innen. Beteiligte Einrichtung: Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Neoplasms, Drug Resistance, Neoplasm, Tumor Escape. Die Arbeit nennt 130 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiopharmaceutical therapy (RPT) has transformed the management of metastatic castration-resistant prostate cancer and neuroendocrine tumors, with clinical development extending to renal cell carcinoma, hepatocellular carcinoma, lung cancer, and breast cancer. Because relapse after RPT occurs across cancer types, there is an urgent need to implement new treatment strategies to overcome resistance and achieve more durable responses. Here, we summarize recent advances in research concerning RPT resistance mechanisms involving tumor cell-intrinsic signaling, the tumor immune microenvironment, and tumor metabolism, as well as emerging strategies to overcome them. We also highlight progress in advanced preclinical models that better recapitulate human metabolism and immune responses, which are essential for validating new combination approaches designed to maximize the clinical benefit of RPT, with a focus on prostate cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RadiopharmaceuticalsNeoplasmsDrug Resistance, NeoplasmTumor EscapeHumansAnimalsTumor Microenvironment

Stichwörter der Autor:innen

RPT combinationsdosimetrypreclinical modelsradiobiologyradionuclide therapyradiopharmaceuticals

Substanzen

Radiopharmaceuticals

Autor:innen und Institutionen

  • Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California.
  • Ahmanson Translational Theranostics Division, David Geffen School of Medicine, UCLA, Los Angeles, California cmona@mednet.ucla.edu.

Zitieren

APA

Abt, E. R., Radu, C. G., Czernin, J., & Mona, C. E. (2026). Radiopharmaceutical Therapy–Linked Tumor Resistance: Immune Evasion, Nonimmune Mechanisms, and Immunometabolic Vulnerabilities. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.269489

Vancouver

Abt ER, Radu CG, Czernin J, Mona CE. Radiopharmaceutical Therapy–Linked Tumor Resistance: Immune Evasion, Nonimmune Mechanisms, and Immunometabolic Vulnerabilities. Journal of Nuclear Medicine. 2026. doi:10.2967/jnumed.125.269489

BibTeX
@article{Abt2026,
  author = {Abt, Evan R and Radu, Caius G and Czernin, Johannes and Mona, Christine E},
  title = {Radiopharmaceutical Therapy–Linked Tumor Resistance: Immune Evasion, Nonimmune Mechanisms, and Immunometabolic Vulnerabilities},
  journal = {Journal of Nuclear Medicine},
  year = {2026},
  doi = {10.2967/jnumed.125.269489}
}
Kostenlos starten →